^
    Back
    Association details:
    Biomarker:CD8 expression
    Cancer:Urothelial Cancer
    Drug:sasanlimab (PF-06801591) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    AACR-II 2020
    Title:

    Abstract CT138: Molecular markers in a phase I dose expansion study of PF-06801591 in locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma

    Published date:
    04/27/2020
    Excerpt:
    In UC, certain high baseline CD8 levels by IHC were associated with better ORR, PFS and OS.
    DOI:
    10.1158/1538-7445.AM2020-CT138
    Trial ID:
    NCT02573259